Your browser doesn't support javascript.
loading
Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients.
Kubota, Akira; Maeda, Hajime; Kanamori, Akira; Matoba, Kiyokazu; Jin, Yasuyuki; Minagawa, Fuyuki; Obana, Mitsuo; Iemitsu, Kotaro; Ito, Shogo; Amamiya, Hikaru; Kaneshiro, Mizuki; Takai, Masahiko; Kaneshige, Hideaki; Hoshino, Kazuhiko; Ishikawa, Masashi; Minami, Nobuaki; Takuma, Tetsuro; Sasai, Nobuo; Aoyagi, Sachio; Kawata, Takehiro; Mokubo, Atsuko; Takeda, Hiroshi; Honda, Shin; Machimura, Hideo; Motomiya, Tetsuya; Waseda, Manabu; Naka, Yoshikazu; Tanaka, Yasushi; Terauchi, Yasuo; Matsuba, Ikuro.
Affiliation
  • Kubota A; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Maeda H; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Kanamori A; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Matoba K; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Jin Y; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Minagawa F; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Obana M; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Iemitsu K; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Ito S; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Amamiya H; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Kaneshiro M; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Takai M; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Kaneshige H; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Hoshino K; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Ishikawa M; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Minami N; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Takuma T; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Sasai N; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Aoyagi S; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Kawata T; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Mokubo A; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Takeda H; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Honda S; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Machimura H; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Motomiya T; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Waseda M; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Naka Y; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
  • Tanaka Y; Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine.
  • Terauchi Y; Department of Endocrinology and Diabetes, Yokohama City University Medical Center, Kanagawa, Japan.
  • Matsuba I; The Study Group of the Diabetes Committee, Kanagawa Physicians Association.
J Diabetes Investig ; 3(6): 503-9, 2012 Dec 20.
Article in En | MEDLINE | ID: mdl-24843615
ABSTRACT
UNLABELLED (J Diabetes Invest, doi 10.1111/j.2040-1124.2012.00221.x, 2012) Aims/

Introduction:

To determine the efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients after 3 months' therapy. MATERIALS AND

METHODS:

A retrospective, observational study of 741 type 2 diabetes patients was carried out; 110 received sitagliptin monotherapy, and 631 received combination therapy with sitagliptin when other oral medications were insufficient. The primary outcome measure was glycated hemoglobin (HbA1c) measured at 0, 4 and 12 weeks of sitagliptin therapy.

RESULTS:

In the monotherapy and combination therapy groups, HbA1c decreased significantly after 12 weeks. Target HbA1c (<7%) was achieved in 39.1% overall. On logistic regression analysis, baseline HbA1c was the strongest contributing factor for achieving target HbA1c; baseline body mass index and duration of diabetes were also significant factors. A total of 82 patients (11%) were unresponsive to sitagliptin. These patients' baseline body mass index was significantly higher and their baseline HbA1c was significantly lower than those of patients who responded to sitagliptin. The most commonly co-administered drugs were sulfonylureas (508 patients). In these patients, the dose of sulfonylurea decreased with time. In 66 patients whose sulfonylurea dosage was reduced when sitagliptin was started, HbA1c and bodyweight decreased significantly after 12 weeks. A total of 24 patients receiving sulfonylureas had mild hypoglycemia, but none discontinued sitagliptin.

CONCLUSIONS:

Sitagliptin was effective and safe as both monotherapy and combination therapy in Japanese type 2 diabetes patients. When sulfonylureas were ineffective, sitagliptin improved glycemic control. In patients whose sulfonylurea dose was reduced at the start of sitagliptin, blood glucose improved and bodyweight decreased after 12 weeks.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies Language: En Journal: J Diabetes Investig Year: 2012 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies Language: En Journal: J Diabetes Investig Year: 2012 Document type: Article